Engineered external guide sequences effectively block viral gene expression and replication in cultured cells.
Ribonuclease P (RNase P) complexed with external guide sequence (EGS) represents a novel nucleic acid-based gene interference approach to modulate gene expression. We have previously used an in vitro selection procedure to generate EGS variants that efficiently direct human RNase P to cleave a target mRNA in vitro. In this study, a variant was used to target the mRNA encoding the protease of human cytomegalovirus (HCMV), which is essential for viral capsid formation and replication. The EGS variant was about 35-fold more active in inducing human RNase P to cleave the mRNA in vitro than the EGS derived from a natural tRNA. Moreover, a reduction of 95% in the expression of the protease and a reduction of 4,000-fold in viral growth were observed in HCMV-infected cells that expressed the EGS variant, whereas a reduction of 80% in the protease expression and an inhibition of 150-fold in viral growth were detected in cells that expressed the EGS derived from a natural tRNA sequence. No significant reduction in viral protease expression or viral growth was observed in cells that either did not express an EGS or produced a "disabled" EGS, which carried nucleotide mutations that precluded RNase P recognition. Our results provide direct evidence that engineered EGS variant is highly effective in blocking HCMV expression and growth by targeting the viral protease. Furthermore, these results demonstrate the utility of engineered EGS RNAs in gene targeting applications, including the inhibition of HCMV infection by blocking the expression of virus-encoded essential proteins.
Jiang
Xiaohong
X
School of Life Sciences, Nanjing University, Nanjing, Jiangsu 210093, China.
Bai
Yong
Y
Rider
Paul
P
Kim
Kihoon
K
Zhang
Chen-Yu
CY
Lu
Sangwei
S
Liu
Fenyong
F
D001483:Base Sequence; D002213:Capsid / Q000201:enzymology / Q000378:metabolism; D003587:Cytomegalovirus / Q000201:enzymology / Q000235:genetics* / Q000254:growth & development / Q000502:physiology*; D004261:DNA Replication / Q000235:genetics; D005240:Feasibility Studies; D015967:Gene Expression Regulation, Viral / Q000235:genetics*; D005814:Genes, Viral / Q000235:genetics; D005818:Genetic Engineering / Q000379:methods*; D006367:HeLa Cells; D006801:Humans; D010447:Peptide Hydrolases / Q000172:deficiency / Q000235:genetics; D034622:RNA Interference; D012333:RNA, Messenger / Q000235:genetics; D043262:Ribonuclease P / Q000378:metabolism; D014779:Virus Replication / Q000235:genetics*
D012333:RNA, Messenger; D043262:Ribonuclease P; D010447:Peptide Hydrolases